Support Us

Help ease the burden of disease for more than 1 billion people worldwide.

YOU CAN HELP

Help make medicines accessible for everyone

Over 1 billion people live with neglected diseases, simply because there's no financial incentive to fund the long and costly work of developing a medicine.

At Medicines Development for Global Health, we're working to change that. We develop medicines that ease the burden on some of the world's most disadvantaged people and communities, and we need strong philanthropic support to keep going.

Together we can improve lives, transform communities and build a fairer, healthier world.

Will you join us in making medicines accessible to everyone? Speak with our team about funding opportunities today.

Speak with our team

Join us

Help us bring neglected diseases closer to elimination

Support us

Donations & Philanthropic giving

Support the development of life-changing medicines for over one billion people affected by neglected diseases.

Donate today

Workplace Giving

Make regular pre-tax donations that help accelerate access to vital treatments for underserved communities.

Contact us

Impact Investing

Invest in the development of new medicines for neglected diseases, with the opportunity for financial return and measurable global impact.

Learn more

MDGH is currently developing two medicines: moxidectin and dovramilast.

Together, these medicines are targeting seven different diseases that collectively impact more than 1 billion people. With your support we can continue to progress the development of these medicines.

It costs us (USD):

$1.5M - $10M

to run one clinical trial

~$150,000

to manufacture one batch of medicine

~$5,000

to support one participant in a clinical trial

~$20,000

to provide clinical trial supplies to one site

We have the expertise and tools required to develop and deliver medicines for the treatment of numerous neglected diseases, and there is potential for millions of people to benefit from our work. But we need your support.

our work

See our latest projects

Leprosy type 2 reaction: Phase 2 clinical study

We are developing dovramilast, an investigative medicine which offers the potential as a more effective, better-tolerated, and easier-to-administer alternative for people affected by leprosy type 2 reaction.

River blindness: Moxidectin rollout in Ghana

Since its rollout in January 2025, moxidectin has improved the lives of over 120,000 people living in Ghana.

Children smiling outside a village building

Nigeria alone could gain approximately US$19bn in increased productivity by meeting its 2030 elimination targets

Read 2023 end fund report